Your browser doesn't support javascript.
loading
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Patel, Hiten D; Puligandla, Maneka; Shuch, Brian M; Leibovich, Bradley C; Kapoor, Anil; Master, Viraj A; Drake, Charles G; Heng, Daniel Yc; Lara, Primo N; Choueiri, Toni K; Maskens, Deborah; Singer, Eric A; Eggener, Scott E; Svatek, Robert S; Stadler, Walter M; Cole, Suzanne; Signoretti, Sabina; Gupta, Rajan T; Michaelson, Marc Dror; McDermott, David F; Cella, David; Wagner, Lynne I; Haas, Naomi B; Carducci, Michael A; Harshman, Lauren C; Allaf, Mohamad E.
Afiliación
  • Patel HD; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Puligandla M; Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Shuch BM; Department of Urology, Yale School of Medicine, New Haven, CT, USA.
  • Leibovich BC; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Kapoor A; Division of Urology, McMaster University, Hamilton, ON, Canada.
  • Master VA; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
  • Drake CG; Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
  • Heng DY; Tom Baker Cancer Center, Calgary, AB, Canada.
  • Lara PN; Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
  • Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Maskens D; Kidney Cancer Canada, Toronto, Ontario, Canada.
  • Singer EA; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Eggener SE; Section of Urology, University of Chicago, Chicago, IL, USA.
  • Svatek RS; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  • Stadler WM; Department of Medicine (Hematology/Oncology), University of Chicago, Chicago, IL, USA.
  • Cole S; Department of Medicine (Hematology/Oncology), University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Signoretti S; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.
  • Gupta RT; Departments of Radiology & Surgery & The Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Michaelson MD; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • McDermott DF; Division of Hematology-Oncology & Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Cella D; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Wagner LI; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Haas NB; Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, PA, USA.
  • Carducci MA; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Harshman LC; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Allaf ME; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Future Oncol ; 15(15): 1683-1695, 2019 May.
Article en En | MEDLINE | ID: mdl-30968729
ABSTRACT
Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. There is emerging data across other solid tumors of the potential efficacy of neoadjuvant PD-1 blockade, and preclinical evidence supporting a neoadjuvant over adjuvant approach. PROSPER RCC is a Phase III, randomized trial evaluating whether perioperative nivolumab increases recurrence-free survival in patients with high-risk RCC undergoing nephrectomy. The neoadjuvant component, intended to prime the immune system for enhanced efficacy, distinguishes PROSPER from other purely adjuvant studies and permits highly clinically relevant translational studies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos Clínicos / Atención Perioperativa / Neoplasias Renales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Future Oncol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos Clínicos / Atención Perioperativa / Neoplasias Renales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Future Oncol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos